Synlogic, Inc. (OTC: SYBX) (“Synlogic”) and Caldera Therapeutics, Inc. (“Caldera”), a privately held clinical-stage biotechnology company developing CLD-423, a potential first-in-class TL1A x IL-23p19 bispecific antibody for inflammatory bowel disease (IBD) and other immune-mediated diseases, announce that they have entered into a definitive merger agreement to combine in an all-stock transaction. Upon closing, the combined company plans to operate under the name Caldera Therapeutics, Inc. and intends to apply to trade on the Nasdaq Capital Market under the ticker symbol “CALD.”
Read the full article: Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement //
Source: https://www.businesswire.com/news/home/20260729485031/en/Synlogic-and-Caldera-Therapeutics-Announce-Merger-Agreement-and-Concurrent-Private-Placement